Abstract | Many non-infectious neurodegenerative diseases are associated with the accumulation of fibrillar proteins. These diseases all exhibit features that are reminiscent of those of prionopathies, including phenotypic diversity and the propagation of pathology. Furthermore, emerging studies of amyloid-β, α-synuclein and tau -proteins implicated in common neurodegenerative diseases -suggest that they share key biophysical and biochemical characteristics with prions. Propagation of protein misfolding in these diseases may therefore occur through mechanisms similar to those that underlie prion pathogenesis. If this hypothesis is verified in vivo, it will suggest new therapeutic strategies to block propagation of protein misfolding throughout the brain.
Prionopathies are unique among neuro degenerative diseases because they are infectious -that is, spontaneous transmis sion from one individual to another has occurred outside an experimental setting. Prion diseases result from protein misfold ing, which in rare cases can be due to expo sure to exogenous prion species 1 -that is, infection -but is usually due to events that occur spontaneously in the individual. The nonpathogenic form of the prion protein (PrP C ) is expressed in many human cell types 2 . When PrP C comes into contact with a pathogenic prion protein conformer (PrP Sc ), it is induced to misfold in a process known as templated conformation change. Through this interaction, the conformation of a PrP Sc molecule is communicated to a native PrP C protein 3 . This interaction may involve other proteins in the cell, and it is unknown whether one or more PrP Sc molecules is required to form the pathogenic 'seed' .
Recent studies have highlighted prion like mechanisms of propagation of protein misfolding in various common, non infectious neurodegenerative diseases (those in which transmission between individuals has never been shown outside experimental conditions), such as Alzheimer's disease (AD), frontotemporal dementia (FTD), Parkinson's disease (PD) and polyglutamine diseases (TABLE 1) . Like prionopathies, all of these diseases are associated with the accu mulation of fibrillar aggregates of proteins -tau, amyloidβ (Aβ), αsynuclein and polyglutamine proteins. With the exception of polyglutamine diseases, which arise from an unusual genetic mutation that produces a protein containing an abnormally long glutamine tract, sporadic cases of these diseases involve the wildtype form of each gene, whereas rarer, autosomal dominant forms of the diseases are linked to missense or splicing mutations. Similarly, although prion diseases are defined by their infectivity, most prion disease cases actually arise spo radically from wildtype protein or through inherited mutations in the prion protein 4 . This article highlights two important commonalities between prion and non prion neurodegenerative diseases -phe notypic diversity and spreading pathology -and reviews the basic research that is beginning to elucidate the biochemical and cellular basis of these similarities.
Phenotypic diversity
Most common neurodegenerative diseases manifest myriad phenotypes. In AD, the speed of cognitive decline, age of onset and the location and extent of Aβ plaque load vary considerably [5] [6] [7] . Aβ aggregates are also present in muscle fibres in inclu sion body myositis, a common agerelated inflammatory muscle disease 8 , and in the vascular wall in cerebral amyloid angio pathy 9 . PD, dementia with Lewy bodies and multiple system atrophy are all associ ated with αsynuclein deposition 10 but are strikingly distinct clinical syndromes. PD is associated with αsynuclein missense mutations 11, 12 and gene amplification [13] [14] [15] . Most remarkably, tau aggregation is a path ological hallmark of more than 20 differ ent neurodegenerative diseases, including AD 10 and frontotemporal dementia with Parkinsonism, a familial disease caused by mutations in the tau gene 10 . Sporadic tauopathies vary considerably in brain region involvement, disease duration, age of onset and fibril morphology 10 . Prion diseases also have diverse pheno types, involving both the CNS and PNS, exhibit distinct rates of progression 16, 17 and can derive from mutations in the prion protein gene 18 . The wildtype prion protein (PrP) is the causative agent for Kuru 19 and sporadic CreutzfeldtJakob Disease (CJD), among others. Prions also cause fatal familial insomnia [20] [21] [22] . Thus, variation in the presentation and course of the disease defines both prion and nonprionbased neurodegeneration. Distinct conformations of pathogenic proteins could have a key role in determining the phenotypic diversity of noninfectious neurodegenerative diseases.
Underlying mechanisms: conformations and strains? In the case of the prion dis eases, it is thought that distinct conform ers, or strains, of prion fibril underlie different disease phenotypes. Depending on various factors, including amino acid sequence, posttranslational modifications and aggregation conditions, PrP Sc assem bles into multiple individually self propagating conformations that gener ate these distinct disease phenotypes in humans and mice [22] [23] [24] . It is not yet possible to predict the specific phenotype that will result from a given PrP Sc conformation in mammals. However, the yeast prion Sup35 has helped inform our understanding of mammalian prions. Sup35 alternates between a soluble (active) and aggregated (inactive) state. The aggregation state of Sup35 is transmitted in a heritable, epige netic fashion from parent to daughter yeast cell. The rate of growth and fibril fragility determine the efficiency with which pro tein aggregates are passed from mother to daughter cells 25 , and these biochemical features have been directly linked to fibril structure 26 . This level of structural detail is not yet available for PrP Sc ; however, recent work in mouse models indicates that unique prion strains correlate with the sen sitivity of the associated fibrils to in vitro denaturation 24 . To what extent can conformational diversity explain the diverse phenotypes of the noninfectious neurodegenerative diseases? The conformational diversity of various amyloid proteins is now widely rec ognized. For example, tau fibrils can exist in several distinct structures that are stable over serial seeding reactions 27 . Wildtype, ΔK280 and P301L;v337M doublemutant fibrils are conformationally distinct when prepared in vitro. When mutant tau seeds are used to induce fibrillization of wild type monomer, the resulting fibrils closely resemble the conformation of the mutant seed and are distinct from the wildtype fibril conformation 27 . Distinct, selfpropagating fibril struc tures have also been documented for Aβ 28 and αsynuclein 29 , putting these proteins in the same biochemical class as prions. even the growth conditions of in vitro Aβ fibrillization reactions have been shown to specify the conformation of the resultant fibrils 28 . Aβ fibrils assume one of two distinct conformations, depend ing on whether the reactions are gently agitated. When incubated with fresh Aβ monomer, each fibril type faithfully propagates the original conformation over successive seeding reactions. The two Aβ fibril conformations have distinct tox icities when added to primary neurons 28 . Although intriguing, this artificial readout of fibril toxicity is of unknown significance in relation to the diversity of human dis ease, and thus at this stage one can only speculate as to the effect of distinct Aβ conformers on AD phenotypes in vivo.
αSynuclein proteins also exhibit fibril lar conformational diversity, as missense mutations that are responsible for domi nantly inherited synucleinopathy produce fibrils that are conformationally distinct from wildtype fibrils 29, 30 . In vitro studies indicate that mutant fibrils can transmit their conformation to wildtype protein, driving it into a new conformation that resembles the original mutant seed 29 . Again, however, there is as yet no evidence that distinct synuclein structures underlie the various synucleinopathy phenotypes.
Taken together, these in vitro studies indicate that tau, Aβ and αsynuclein are all capable of the type of templated con formation change that was first described for prions. Like prions, these proteins also form distinct conformers in vivo that could cause variation in regional pathology and disease progression. extrapolating from fundamental research in prion biology, which indicates that factors such as chap erones can modify prion amplification rates, formation of these distinct conform ers could be influenced by specific protein interactions or posttranslational modi fications. These extragenic effects might manifest as genetic modifiers of patho genesis, just as the presenilins increase AD risk by augmenting production of Aβ. Additionally, aggregates could pro duce unique patterns of disease through conformationspecific interactions with other cellular factors, which likewise might appear as genetic modifiers. The relative ease with which it is possible to generate distinct protein fibril conformers in vitro indicates that there might be even more pathological syndromes than those of which we are currently aware. However, until distinct mammalian pathologies are clearly linked to discrete protein conforma tions, or genetic modifiers in humans are directly associated with the production of unique fibril conformations, it will be unclear whether prionlike conformational diversity of pathological proteins accounts for phenotypic variation in the common neurodegenerative diseases.
Spreading pathology
Neurodegenerative diseases begin with dysfunction in a discrete region, whereas at later stages they typically involve much larger areas of the brain. Pathology often occurs in particular neural networks and progresses in a predictable manner. For example, the transentorhinal region is the first area to show signs of deterioration and tau pathology in AD. Glutamatergic cells in this region project into the entorhinal cortex, which is the next area to degenerate. Lesions of the hippocampus, amygdala and neocortex follow 31 . Recent studies of patients with and without dementia using functional imaging have corroborated these pathological stud ies and have shown that degeneration in distinct neurodegenerative diseases such as AD, corticobasal ganglionic degenera tion and FTD follow normal patterns of intrinsic neuronal connectivity 32 . PD is well known to begin with motor symptoms that are largely caused by the degeneration of dopaminergic neurons in the substan tia nigra; however, a substantial fraction of patients go on to develop dementia, implying that additional brain regions are involved 33 . Likewise, in amyotrophic Sc injected into the eye travels along defined neuroanatomical connections to reach larger brain regions 37, 38 .
Underlying mechanisms: cell-to-cell transmission? The propagation of PrP misfold ing between cells follows a model in which PrP
Sc travels from an infected cell to a naive cell, whereupon it encounters PrP C and converts it to PrP Sc (REf. 38) . These features of prion disease suggest that PrP Sc may gain access to a connected neuron by travers ing the synapse, or that PrP Sc released into the extracellular space may be taken up by nearby cells. Cell culture studies support these hypotheses. Cultured primary mouse neurons spontaneously take up fibrillar PrP, which localizes to late endosomes and/or lysosomes 39 . PrP aggregates may transfer between cultured cells through exosomes 40 or tunneling nanotubes 41 , which are putative cytoplasmic con nections between mammalian cells 42 . Determining whether these events underlie the spread of prion pathology in vivo will require more mechanistic studies involving targeted disruption of these processes.
It is unknown whether nonprion protein aggregates move between cells in humans. Pathological studies of patients with PD who underwent fetal transplant surgery are provocative but not conclusive. In these reports, engrafted mesencephalic dopaminergic neurons developed ubiqui tin and αsynucleinpositive Lewy bodies, many of which were indistinguishable from lesions in the diseased host [43] [44] [45] . Recent studies in mice have essentially replicated the work in patients: synucleinnegative cells were transplanted into a human synucleintransgenic mouse, where they developed Lewy bodies 46 . This investiga tion clearly indicates that synuclein is capa ble of transcellular movement in vivo, and has obvious implications for the potential of aggregated protein to spread pathology from cell to cell in humans.
Whether aggregates can transfer directly between cells in vivo is unknown, but cell culture studies suggest this is pos sible. For example, aggregates comprised of Aβ, αsynuclein, tau and polyglutamine proteins are readily internalized by cultured cells 39, [46] [47] [48] [49] [50] . In the case of poly glutamine proteins, the uptake of an aggre gate causes the wildtype (unexpanded) form of the protein expressed in the cell to misfold 50 . Similarly, internalized tau aggregates seem to interact directly with normally folded tau and trigger its fibrilli zation 49 . Intracellular tau aggregates can also transfer between cocultured cells 49 . Thus, tau and polyglutamine proteins, like prions, can 'transmit' a misfolded state from the outside of a cell to the inside. This idea is supported by the observation that the yeast prion, Sup35, can accomplish transcellular propagation of aggregates when expressed in mammalian cells 51 . Although the results of these experiments are intriguing, a clearer interpretation will require the definition of basic mechanisms of uptake and cell-cell transfer, as well as the demonstration that this influences propagation of pathology in vivo.
Intracerebral injection of human or mouse AD brain material can initiate Aβ pathology in transgenic mice 52 . It has also been observed recently that microinjec tions of brain extracts from transgenic mice expressing mutant human tau protein induce misfolding of endogenous tau in recipient mice. It was suggested that the induced tau misfolding propagated beyond the site of injection. Indeed, tau protein must be present in the injected material for this effect to manifest, which hints at a 'prionlike' mechanism 53 , although it is hard to rule out diffusion of the injected material accounting for the apparent propagation of endogenous tau misfold ing. Although sporadic neurodegenerative diseases do not derive from injected brain extracts, these studies indicate that mis folding can somehow be communicated from the extracellular to the intracellular space, as was previously observed with tau in tissue culture 49 . It has not yet been demonstrated in vivo that a misfolded pro tein in one cell can directly trigger misfold ing in a connected cell, which would more explicitly test the idea that AD, tauopathy or synucleinopathies involve prionlike mechanisms. In addition it should be emphasized that there is no evidence that these disorders have ever been transmit ted between individuals as bona fide prionopathies.
Distinctions between diseases
Crucial distinctions remain between the prionopathies and common neurodegen erative diseases. Most importantly, there is no evidence, despite decades of study, of true, spontaneous infectivity for any spo radic disease such as AD, FTD or PD. The biophysical properties that allow a protein that has been eaten, passed through the digestive system and absorbed to replicate in the host and make its way to the brain clearly set prion proteins apart from any other known amyloid protein associated with neurodegenerative disease. However, serum amyloidosis A (SAA) has been studied as another potentially infectious amyloid disease 54 . It is caused by misfold ing of the serum amyloid A protein 55 and although not associated with neuro degeneration has many features similar to prionopathies, including an oral route of transmission 56 . Most prionopathies exhibit relatively rapid progression in the CNS, with sCJD averaging 4-6 months from symptom onset to death 57 , whereas common neuro degenerative diseases generally progress over many years. Furthermore, PrP is a transmembrane protein, which could in theory more easily allow transcellular propagation, whereas tau and synuclein normally function within the cell. Thus, it is more difficult to understand how they could accomplish transcellular movement.
A common model of propagation? even taking into account these distinctions, increasing experimental evidence is now indicating that the basic cellular mecha nisms of transcellular prion propagation may be applicable to a wide range of protein pathologies. In this model (fIG. 1) 58, 59 . Finally, as mechanisms of aggregate uptake and celltocell transmis sion are determined, it may be possible to design new pharmacological interventions that block disease progression (fIG. 2) .
Conclusions various neurodegenerative disease associated proteins exhibit templated con formational change, which might underlie certain aspects of the phenotypic diversity of these diseases. Given the clear predic tions of this model, future studies should be able to explicitly test this idea. The phe nomenon of cell-cell transfer of protein aggregates is now well established in cell culture and mouse models in addition to those based on PrP pathogenesis will allow us to test whether other diseaserelated proteins can trigger a true propagation of misfolding in the manner of prions -that is, will aggregated species released from one cell and taken up by another lead to further aggregation of natively folded spe cies in the recipient cell, and so on? The cellular mechanisms of aggregate release and uptake remain to be elucidated, and whether the same mechanisms apply to all aggregationprone proteins will need to be determined. Similarly, the true range of these phenomena in other neurodegen erative diseases associated with protein misfolding is unknown. For example, will TAR DNAbinding protein 43 or superoxide dismutase 1, both of which are associated with amyotrophic lateral sclerosis, also exhibit such celltocell transfer? It is also unknown what role glia and their proposed cellular mechanisms might have in vivo. Can aggregates trans fer across synapses, and can this account for the propagation of pathology along neural networks? As the current studies and existing knowledge of prion patho genesis are extended and augmented by new findings, a new unifying model that melds cellautonomous and noncell autonomous mechanisms of protein mis folding in neurodegenerative diseases will be required. If trans-cellular propagation of protein misfolding occurs, new strategies could supplement existing approaches to promote cell survival and block intracellular accumulation of misfolded species. As the cellular mechanisms of aggregate release and uptake are delineated, it may be possible to inhibit these events pharmacologically or genetically. Antibody-based therapies might also be expanded to target protein aggregates that are generated inside a cell and released into the extracellular space.
